Market Overview

UPDATE: Citigroup Raises PT on Alkermes on Multiple Value Opportunities

Related ALKS
Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years
Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating
Ad Comm approaches for Fabre-Kramer's MDD med (Seeking Alpha)

In a report published Thursday, Citigroup analyst Jonathan Eckard reiterated a Buy rating on Alkermes PLC (NASDAQ: ALKS), and raised the price target from $38.00 to $43.00.

In the report, Citigroup noted, “We are adding ALKS to the Citi Focus List and increasing our target price on ALKS to $43 from $38 based on our increased estimates for late-stage programs, introduction of estimates for earlier stage programs, and lower outyear tax rate. We believe there are several ALKS programs with significant commercial potential. Considering the breadth of interesting programs in the company's pipeline, we believe that ALKS' relative valuation is discounted compared to other mid-cap biotech companies within the same range of market capitalization.”

Alkermes PLC closed on Wednesday at $32.62.

Latest Ratings for ALKS

Nov 2015Leerink SwannMaintainsOutperform
Oct 2015BarclaysMaintainsOverweight
Oct 2015BarclaysMaintainsOverweight

View More Analyst Ratings for ALKS
View the Latest Analyst Ratings

Posted-In: Citigroup Jonathan EckardAnalyst Color Price Target Analyst Ratings


Related Articles (ALKS)

View Comments and Join the Discussion!

Get Benzinga's Newsletters